Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A Post Hoc analysis of the 2007 national health and wellness survey

Clinical Drug Investigation

Volumn 31, Issue 10, 2011, Pages 703-715

  Toghanian, Samira ^a   Johnson, David A ^b   Stlhammar, Nils Olov ^a   Zerbib, Frank ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Cost of illness; Gastro oesophageal reflux; Proton pump inhibitors; quality of life

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ABSENTEEISM; ADL DISABILITY; ADULT; AGED; ARTICLE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EMERGENCY CARE; FEMALE; FRANCE; GASTROESOPHAGEAL REFLUX; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PHYSICIAN; POST HOC ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SYMPTOM; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; WORK DISABILITY;

ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; DRUG RESISTANCE; FEMALE; FRANCE; GASTROESOPHAGEAL REFLUX; GERMANY; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROTON PUMP INHIBITORS; QUALITY OF LIFE; SELF REPORT; UNITED STATES;

EID: 80052439958     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11595480-000000000-00000     Document Type: Article

References (27)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 Aug; 101 (8): 1900-20
2. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54 (5): 710-7 (Pubitemid 40559260)
3. El-Dika S, Guyatt GH, Armstrong D, et al. The impact of illness in patients with moderate to severe gastroesophageal reflux disease. BMC Gastroenterol 2005; 5: 23
4. Ujszaszy L, Kulich RK, Toth GT, et al. Burden of illness in patients with reflux disease: evidence from a recent comparative methodological study in Hungary. Orv Hetil 2004 Mar 28; 145 (13 Suppl. 2): 717-22, 33-8
5. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006 Jan; 101 (1): 18-28 (Pubitemid 43381704)
6. Wahlqvist P, Karlsson M, Johnson D, et al. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008 May; 27 (10): 960-70 (Pubitemid 351537653)
7. Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol 2001 Aug; 96 (8 Suppl.): S57-61 (Pubitemid 32758211)
8. Wahlqvist P, Brook RA, Campbell SM, et al. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008 Jan; 50 (1): 25-31
9. Wahlqvist P, Guyatt GH, Armstrong D, et al. The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAIGERD): responsiveness to change and English language validation. Pharmacoeconomics 2007; 25 (5): 385-96 (Pubitemid 46744469)
10. Brook RA, Wahlqvist P,Kleinman NL, et al. Cost of gastrooesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007 Sep 15; 26 (6): 889-98 (Pubitemid 47346705)
11. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135 (4): 1383-91
12. Jones R, Liker HR, Ducrotte?P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007 Aug; 61 (8): 1301-7 (Pubitemid 47052376)
13. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 Feb; 10 (2): 119-24 (Pubitemid 28101879)
14. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003 Sep; 98 (9): 1940-4 (Pubitemid 37185787)
15. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcome Manag 2000; 7 (11): 29-34 (Pubitemid 33208979)
16. CHS 2011 [online]. Available from URL: international.com/default.aspx [Accessed 2011 Jan 7]
17. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al.UpperGI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010 Jan; 71 (1): 28-34
18. Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.Med Care 1996Mar; 34 (3): 220-33
19. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities IndexMark II. Pharmacoeconomics 1999 Feb; 15 (2): 141-55 (Pubitemid 29093257)
20. Prasad M, Wahlqvist P, Shikiar R, et al. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004; 22 (4): 225-44 (Pubitemid 38393392)
21. Wahlqvist P, Carlsson J, Stålhammar NO, et al. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD): results from a cross-sectional study. Value Health 2002 Mar-Apr; 5 (2): 106-13 (Pubitemid 34274868)
22. Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther 2006 Jul 15; 24 (2): 259-72 (Pubitemid 43972894)
23. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008 Jan; 103 (1): 20-6
24. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007 Dec; 5 (12): 1385-91 (Pubitemid 350181597)
25. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010 Aug; 139 (2): 409-17
26. Boeckxstaens GE, Rydholm H, Lei A, et al. Effect of lesogaberan, a novel GABA-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010 Jun; 31: 1208-17
27. Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomized placebo-controlled trial. Gut. Epub 2011 Mar 14